{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:35:03Z","timestamp":1780421703785,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T (CAR T) cell therapy approved for adults with relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL). We studied the impact of social determinants of health (SDoH) on outcomes of adults with B-ALL receiving brexu-cel. This retrospective analysis included adults (\u226518 years) with R\/R B-ALL treated with brexu-cel between 2021 and 2023. Cox proportional hazards models evaluated the association of race, ethnicity, and SDoH with progression-free survival (PFS) and overall survival (OS). 189 patients received brexu-cel and 57% were male. 55% were non-Hispanic White, 30% Hispanic, 7% non-Hispanic Black, 6% Asian\/Pacific Islander, and 2% other\/unknown. 43% were referred from private\/community-based practices and 35% lived 50 miles or greater from the CAR T center. Health insurance included public (47%) and private (41%). 31% had a high social deprivation index (SDI, 76\u201399th percentile). Black race was associated with worse OS (HR 3.48; 95% CI 1.01\u201312.03). There was no difference in PFS (HR 1.03, 95% CI 0.50\u20132.10) or OS (HR 1.43; 95% CI 0.56\u20133.65) in Hispanic patients. Outcomes appear independent of SDoH and SDoH did not impact OS. We observed comparable outcomes to non-Hispanic patients.<\/jats:p>","DOI":"10.1038\/s41409-025-02693-0","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T16:24:14Z","timestamp":1755966254000},"page":"1465-1471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"60","author":[{"given":"Timothy E.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Roloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam E.","family":"Kopmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone E.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikeshan","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Valtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn C.","family":"Dykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mercadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-0623","authenticated-orcid":false,"given":"Matthew P.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kubiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet","family":"Majhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoo","family":"Battiwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mountjoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz A.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Blunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Guzowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus T.","family":"Hoeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-5790","authenticated-orcid":false,"given":"Jozal","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-462X","authenticated-orcid":false,"given":"Joshua","family":"Sasine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspian","family":"Oliai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-5623","authenticated-orcid":false,"given":"Melhem M.","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2587-8955","authenticated-orcid":false,"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Koura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu V.","family":"Kumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica T.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Galal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-3424","authenticated-orcid":false,"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"2693_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2693_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740\u2013753.","journal-title":"N Engl J Med"},{"key":"2693_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u2013847.","journal-title":"N Engl J Med"},{"key":"2693_CR4","doi-asserted-by":"crossref","unstructured":"Kopmar NE, Cassaday RD. Clinical insights on brexucabtagene autoleucel for the treatment of patients with relapsed or refractory B-Cell acute lymphoblastic leukemia. Cancer Manag Res. 2024;16:1587\u20131596.","DOI":"10.2147\/CMAR.S379807"},{"key":"2693_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"2693_CR6","doi-asserted-by":"crossref","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia 2025;39:1058\u20131068.","DOI":"10.1038\/s41375-025-02532-7"},{"key":"2693_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.blre.2018.08.002","volume":"33","author":"E Quiroz","year":"2019","unstructured":"Quiroz E, Aldoss I, Pullarkat V, Rego E, Marcucci G, Douer D. The emerging story of acute lymphoblastic leukemia among the Latin American population \u2013 biological and clinical implications. Blood Rev. 2019;33:98\u2013105. https:\/\/doi.org\/10.1016\/j.blre.2018.08.002.","journal-title":"Blood Rev"},{"key":"2693_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/aje\/kwaa215","volume":"190","author":"Q Feng","year":"2021","unstructured":"Feng Q, De Smith AJ, Vergara-Lluri M, Muskens IS, McKean-Cowdin R, Kogan S, et al. Trends in acute lymphoblastic leukemia incidence in the United States by race\/ethnicity from 2000 to 2016. Am J Epidemiol. 2021;190:519\u2013527.","journal-title":"Am J Epidemiol"},{"key":"2693_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ajh.26156","volume":"96","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, et al. Acute lymphoblastic leukemia: a population- based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980\u20132017. Am J Hematol. 2021;96:650\u2013658.","journal-title":"Am J Hematol"},{"key":"2693_CR10","volume":"7","author":"KC Dykes","year":"2024","unstructured":"Dykes KC, Chou J, Taylor AO, Shu AC, Mudra SE, Ma X, et al. Survival outcomes in older adult acute lymphoblastic leukemia patients analyzed by facility volume and type: a National Cancer Database Analysis. Cancer Rep. 2024;7:e2162.","journal-title":"Cancer Rep"},{"key":"2693_CR11","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","volume":"115","author":"RC Harvey","year":"2010","unstructured":"Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115:5312\u20135321.","journal-title":"Blood"},{"key":"2693_CR12","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","volume":"129","author":"SC Reshmi","year":"2017","unstructured":"Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children\u2019s Oncology Group. Blood. 2017;129:3352\u20133361.","journal-title":"Blood"},{"key":"2693_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3324\/haematol.2015.136366","volume":"102","author":"T Herold","year":"2017","unstructured":"Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, et al. Adults with philadelphia chromosome\u2013like acute lymphoblastic leukemia frequently have igh-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2017;102:130\u2013138.","journal-title":"Haematologica"},{"key":"2693_CR14","doi-asserted-by":"crossref","unstructured":"Jain N, Roberts KG, Jabbour E, Patel K, Karina Eterovic A, Chen K, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129:572\u2013581.","DOI":"10.1182\/blood-2016-07-726588"},{"key":"2693_CR15","first-page":"1957","volume":"100","author":"S Bhatia","year":"2002","unstructured":"Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood J Am Soc Hematol. 2002;100:1957\u20131964.","journal-title":"Blood J Am Soc Hematol"},{"key":"2693_CR16","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1016\/j.clml.2022.01.001","volume":"22","author":"U Joshi","year":"2022","unstructured":"Joshi U, Khanal S, Bhetuwal U, Bhattarai A, Dhakal P, Bhatt VR. Impact of insurance on overall survival in acute lymphoblastic leukemia: a SEER database study. Clin Lymphoma Myeloma Leuk. 2022;22:e477\u2013e484.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2693_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1475-6773.2012.01449.x","volume":"48","author":"DC Butler","year":"2013","unstructured":"Butler DC, Petterson S, Phillips RL, Bazemore AW. Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Serv Res. 2013;48:539\u2013559.","journal-title":"Health Serv Res"},{"key":"2693_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood-2023-189024","volume":"142","author":"E Shah","year":"2023","unstructured":"Shah E, Avila Rodriguez AM, Luo JW, Cwykiel J, Chasson T, Raigoza E, et al. Individual-level social determinants of health (SDOH) measures and treatment complications in acute leukemia. Blood. 2023;142:374\u2013374.","journal-title":"Blood"},{"key":"2693_CR19","doi-asserted-by":"crossref","unstructured":"Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA. 2003;290:2008\u20132014.","DOI":"10.1001\/jama.290.15.2008"},{"key":"2693_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1182\/bloodadvances.2023011862","volume":"8","author":"H Johnston","year":"2024","unstructured":"Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, et al. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024;8:164\u2013171.","journal-title":"Blood Adv"},{"key":"2693_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1043454220907547","volume":"37","author":"IJ Eche","year":"2020","unstructured":"Eche IJ, Aronowitz T. A literature review of racial disparities in overall survival of black children with acute lymphoblastic leukemia compared with white children with acute lymphoblastic leukemia. J Pediatr Oncol Nurs. 2020;37:180\u2013194.","journal-title":"J Pediatr Oncol Nurs"},{"key":"2693_CR22","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","volume":"130","author":"K Kirtane","year":"2017","unstructured":"Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017;130:1699\u20131705. https:\/\/doi.org\/10.1182\/blood-2017-04-778225.","journal-title":"Blood"},{"key":"2693_CR23","first-page":"1831","volume":"23","author":"MI Patel","year":"2012","unstructured":"Patel MI. Understanding disparities in leukemia: a national study. Cancer Causes Control. 2012;23:1831\u20131837.","journal-title":"Cancer Causes Control"},{"key":"2693_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/annonc\/mdu572","volume":"26","author":"ET Petridou","year":"2015","unstructured":"Petridou ET, Sergentanis TN, Perlepe C, Papathoma P, Tsilimidos G, Kontogeorgi E, et al. Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysis. Ann Oncol. 2015;26:589\u2013597.","journal-title":"Ann Oncol"},{"key":"2693_CR25","unstructured":"Baggott C, Kunicki M, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Inferior outcomes among black patients with childhood acute lymphoblastic leukemia following tisagenlecleucel. in 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings, 2021)."},{"key":"2693_CR26","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1182\/blood.2023023447","volume":"143","author":"FL Locke","year":"2024","unstructured":"Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, et al. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood. 2024;143:2722\u20132734.","journal-title":"Blood"},{"key":"2693_CR27","doi-asserted-by":"crossref","unstructured":"Roloff G W, Aldoss I, Kopmar NE, Lin C, Dekker, SE, Gupta, VK, et al. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL. J Clin Oncol. 2025;43:558\u2013566.","DOI":"10.1200\/JCO.24.00321"},{"key":"2693_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","volume":"8","author":"LC Peres","year":"2024","unstructured":"Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, et al. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024;8:251\u2013259.","journal-title":"Blood Adv"},{"key":"2693_CR29","first-page":"356.e1","volume":"29","author":"AG Hall","year":"2023","unstructured":"Hall AG, Winestone LE, Sullivan EM, Wu Q, Lamble AJ, Walters MC, et al. Access to chimeric antigen receptor T cell clinical trials in underrepresented populations: a multicenter cohort study of pediatric and young adult acute lymphobastic leukemia patients. Transpl Cell Ther. 2023;29:356.e1\u2013356.e7.","journal-title":"Transpl Cell Ther"},{"key":"2693_CR30","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","volume":"6","author":"AJ Faruqi","year":"2022","unstructured":"Faruqi AJ, Ligon JA, Borgman P, Steinberg SM, Foley T, Little L, et al. The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Adv. 2022;6:6040\u20136050.","journal-title":"Blood Adv"},{"key":"2693_CR31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/OP.23.00373","volume":"19","author":"LS Muffly","year":"2023","unstructured":"Muffly LS, Parsons HM, Miller K, Li Q, Brunson A, Keegan TH. Impact of specialized treatment setting on survival in adolescent and young adult ALL. JCO Oncol Prac. 2023;19:1190\u20131198.","journal-title":"JCO Oncol Prac"},{"key":"2693_CR32","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1200\/JCO.2014.55.6258","volume":"32","author":"GV Walker","year":"2014","unstructured":"Walker GV, Grant SR, Guadagnolo BA, Hoffman KE, Smith BD, Koshy M, et al. Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol. 2014;32:3118\u20133125.","journal-title":"J Clin Oncol"},{"key":"2693_CR33","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1377\/hlthaff.2020.01839","volume":"40","author":"GA Silvestri","year":"2021","unstructured":"Silvestri GA, Jemal A, Yabroff KR, Fedewa S, Sineshaw H. Cancer outcomes among medicare beneficiaries and their younger uninsured counterparts. Health Aff. 2021;40:754\u2013762.","journal-title":"Health Aff"},{"key":"2693_CR34","first-page":"714","volume":"30","author":"N Ahmed","year":"2024","unstructured":"Ahmed N, Sun F, Teigland C, Kilgore KM, Mohammadi I, Chambers J, et al. Chimeric antigen receptor T-Cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers. Transpl Cell Ther. 2024;30:714\u2013725.","journal-title":"Transpl Cell Ther"},{"key":"2693_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care\u2014a health economics approach: an ispor special task force report [3]. Value Health. 2018;21:131\u2013139.","journal-title":"Value Health"},{"key":"2693_CR36","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1111\/ajco.13797","volume":"19","author":"AM Belyaev","year":"2023","unstructured":"Belyaev AM, Lewis C, Doocey R, Bergin CJ. The association of socioeconomic deprivation with access and survival after hematopoietic stem cell transplantation in New Zealand. Asia Pac J Clin Oncol. 2023;19:e89\u2013e95.","journal-title":"Asia Pac J Clin Oncol"},{"key":"2693_CR37","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10900-013-9681-1","volume":"38","author":"ST Syed","year":"2013","unstructured":"Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Community Health. 2013;38:976\u2013993. https:\/\/doi.org\/10.1007\/s10900-013-9681-1.","journal-title":"J Community Health"},{"key":"2693_CR38","doi-asserted-by":"crossref","unstructured":"Thiel G, Schmit-Pokorny K, Swanson Rn D, Rn Bsn, DJ, Franco Rn T, Shostrom VK, et al. Assessment of time to insurance approval and distance traveled in patients treated with CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Biol Blood Marrow Trans. 26:S272.","DOI":"10.1016\/j.bbmt.2019.12.441"},{"key":"2693_CR39","first-page":"S216","volume":"30","author":"T Cox","year":"2024","unstructured":"Cox T, Carelock T, Zahradka N, Pugmire J, Wilkes M, Campo R, et al. Remote Patient Monitoring (RPM) technology with centralized virtual nurse monitoring for safe delivery of outpatient chimeric antigen receptor T-Cell (CAR-T) therapy across multiple Sarah Cannon transplant and cellular therapy network programs. Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther. 2024;30:S216\u2013S217.","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"2693_CR40","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjh.18339","volume":"198","author":"B Dholaria","year":"2022","unstructured":"Dholaria B, Mehraban N, Baer B, Long N, Jayani RV, Byrne MT, et al. Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience. Br J Haematol. 2022;198:1073\u20131075. https:\/\/doi.org\/10.1111\/bjh.18339.","journal-title":"Br J Haematol"},{"key":"2693_CR41","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1007\/s12325-021-01839-y","volume":"38","author":"S Snyder","year":"2021","unstructured":"Snyder S, Albertson T, Garcia J, Gitlin M, Jun MP. Travel-related economic burden of chimeric antigen receptor T cell therapy administration by site of care. Adv Ther. 2021;38:4541\u20134555.","journal-title":"Adv Ther"},{"key":"2693_CR42","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","volume":"38","author":"S Snyder","year":"2021","unstructured":"Snyder S, Chung KC, Jun MP, Gitlin M. Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma. Adv Ther. 2021;38:4659\u20134674.","journal-title":"Adv Ther"},{"key":"2693_CR43","first-page":"100454","volume":"20","author":"V Chalfant","year":"2023","unstructured":"Chalfant V, Riveros C, Bradfield SM, Stec AA. Impact of social disparities on 10 year survival rates in paediatric cancers: a cohort study. Lancet Reg Health Am. 2023;20:100454.","journal-title":"Lancet Reg Health Am"},{"key":"2693_CR44","doi-asserted-by":"publisher","first-page":"e0255171","DOI":"10.1371\/journal.pone.0255171","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Khullar D, Wang F, Steel P, Wu Y, Orlander D, et al. Socioeconomic variation in characteristics, outcomes, and healthcare utilization of COVID-19 patients in New York City. PLoS One. 2021;16:e0255171.","journal-title":"PLoS One"},{"key":"2693_CR45","first-page":"183","volume":"22","author":"CB Parraga","year":"2023","unstructured":"Parraga CB, Singh R, Lin R, Tamariz L, Palacio A. Colorectal cancer screening disparities among race: a zip code level analysis. Clin Colorectal Cancer. 2023;22:183\u2013189.","journal-title":"Clin Colorectal Cancer"},{"key":"2693_CR46","doi-asserted-by":"publisher","first-page":"11824","DOI":"10.3390\/ijerph182211824","volume":"18","author":"OA Babatunde","year":"2021","unstructured":"Babatunde OA, Zahnd WE, Eberth JM, Lawson AB, Adams SA, Boakye EA, et al. Association between neighborhood social deprivation and stage at diagnosis among breast cancer patients in South Carolina. Int J Environ Res Public Health. 2021;18:11824.","journal-title":"Int J Environ Res Public Health"},{"key":"2693_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood.2022017866","volume":"141","author":"H Newman","year":"2023","unstructured":"Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood. 2023;141:609\u2013619.","journal-title":"Blood"},{"key":"2693_CR48","doi-asserted-by":"publisher","first-page":"e916","DOI":"10.1016\/S2352-3026(24)00312-0","volume":"11","author":"NP Mayor","year":"2024","unstructured":"Mayor NP, Szydlo RM, Sheikh Y, Lee J, Pearce RM, Farrow C, et al. The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience. Lancet Haematol. 2024;11:e916\u2013e926.","journal-title":"Lancet Haematol"},{"key":"2693_CR49","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","volume":"29","author":"MS Hoffmann","year":"2023","unstructured":"Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma. Transplant Cell Ther. 2023;29:440\u2013448. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.003.","journal-title":"Transplant Cell Ther"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02693-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:20:40Z","timestamp":1762183240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02693-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2693"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02693-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.O.: None C.L.: Advisory board\/Consultancy: Rigel, Autolus, ADC Therapeutics G.W.R.: Kite\/Gilead, Autolus: Advisory board member A.Z.: None K.M.: None I.A.: Consultancy: KiTE, Sobi, Jazz, Pfizer, Amgen, Takeda; Honoraria: Amgen; Advisory board: Amge, Pfizer, Jazz, KiTE, Takeda, Syndax, Sobi, Wugen; Research support: Abbvie, Macrogenics N.E.K.: None S.E.D.: None V.K.G.: None N.J.: None I.N.M.: None Y.V.: None N.A.: None K.S.: Consultancy: OrcaBio K.C.D.: None M.A.: None E.C.: Consultancy: Abbvie H.Z.: None D.B.: None S.M.: None M.S.: Consultancy: Jazz, Novartis S.T.: None M.P.C.: None M.K.: None A.M.: None N.M.: Advisory board: Anthem M.B.: Research funding: Novartis, Fate Therapeutics, L.M.: None S.A.M.: None J.M.: None P.S.: Honoraria: Autolus, BMS; Speakers Bureau: BMS, Sanofi B.B.: None A.C.L.: Research funding: Amgen, Astellas, Autolus, Kadmon, KiTE\/Gilead, Pharmcyclics, Talaris; Consultancy: Abbvie, Amgen, Actinium, BMS, Pfizer, Sanofi, Takeda A.L.: Consultancy: Pfizer, CTI Biopharma A.S.A.: Honoraria\/Consulting\/Advisory Board: Servier, Takeda, Glycomimetics, Pfizer, Novartis, Jazz, KiTE, Amgen; Research funding: OBI, Pfizer, Immunogen\/Abbvie, Kura, Glycomimetics, Seattle Genetics\/Pfizer, Incyte, Beam, KiTE, Amgen, Servier, Glycomimetics M.S.: None C.G.: None R.T.H.: Research funding: OrcaBio T.H.: Consultancy: BeiGene; Research funding: BeiGene J.M.: None K.M.O.: None L.C.H.: Consultancy: March Biosciences; Speaker: KiTE\/Gilead J.S.: None C.O.: Research funding: Novartis, Arog, Orca Bio, Jazz, Pfizer, Seagen M.M.S.: Speakers bureau: Bristol-Myers Squibb C.J.L.: Consultancy: Fresenius Kabi, Sanofi, Incyte Corp; Honoraria: KiTE, BMS, Sanofi, Kadmon; Advisory board: KiTE, Sanofi, Incyte Corp; Speakers bureau: KiTE; Research funding: Incyte corp V.K.K.: Honoraria: KiTE, Novartis, Pfizer; Research funding: Incyte corp D.K.: Consultancy: BMS; Research funding: BMSM.V.: None J.T.L.: Consultancy: Adaptive Biotechnologies, Pfizer, KiTE\/Gilead, Takeda; Advisory board: Adaptive Biotechnologies N.V.F.: None J.H.P.: None M.R.L.: None V.B.: Advisory board: Astra Zeneca, Allogene, BeiGene, CRISPR; DSMB Board: Miltenyi; Research funding: Citius, Incyte corp A.G.: None V.P.: Consultancy: Servier, Amgen, Pfizer, Jazz, Novartis, Genentech, Abbvie; Speakers bureau: Servier, Amgen, Pfizer, Jazz, Novartis, Genentech, Abbvie M.R.B.: Consultancy\/Advisory board: KiTE\/Gilead, Novartis, Bristol Myers Squibb, CRISPR, Autlus, In8bio, Sana Biotechnology, Chimeric Therapeutics, Arcellx, Achieve Clinics; Honoraria: Bristol Myers Squibb, KiTE\/Gilead, Novartis, Incyte, Servier, Sanofi, ADC Therapeutics W.S.: None R.D.C.: Research funding: Servier, Incyte corp, KiTE\/Gilead, Amgen, Vanda Pharmaceuticals, Jazz, Merck, Pfizer; Advisory board: PeproMene Bio, Autolus; Consultancy\/Honoraria: KiTE\/Gilead, Amgen, Jazz, Pfizer; Other: Spouse employed by and owned stock in Seagen within past 24 months B.D.S.: Research funding: Incyte, Jazz, KiTE\/Gilead, Servier; Honoraria: Pharmacyclics\/Janssen, Spectrum\/Acrotech, BeiGene, Gilead Sciences; Other: Travel, accomodations, expenses: KiTE\/Gilead, Stemline Therapeutics, AstraZeneca, Seattle Genetics, Janssen, Pfizer, Novartis, Celgene; Advisory board: DSMC, Pepromene Bio; Consultancy: Takeda, AstraZeneca, Adaptive Biotechnologies, BMS\/Celgene, Novartis, Pfizer, Amgen, Precision Biosciences, KiTE\/Gilead, Jazz, Century Therapeutics, Deciphera, Autolus, Lilly, Pepromene R.F.: Research funding: KiTE\/Gilead, Novartis; Advisory board: KiTE\/Gilead L.S.M.: Consultancy: Amgen, Pfizer, Kite, Autolus, Astellas; Research funding: BMS, Adaptive, Kite, Astellas, Orca Bio, Jasper; Advisory board: Adaptive ST: Advisory board\/Consultancy: Jazz, BMS, Sanofi BD: Institutional research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir, Adicet, BMS, Molecular template, Atara. Consultancy\/Advisor: MJH BioScience, Arivan Research, Janssen, ADC therapeutics, Gilead, GSK, Caribou, Roche, Autolus Permission to reproduce material from other sources: All work within, including, tables and figures within are original to the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}